Antifungal prophylaxis in solid organ transplant recipients

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 5, 2011, Pages 571-581

  Brizendine, Kyle D ^a   Vishin, Sonia ^b   Baddley, John W ^a,c  

^a University of Alabama at Birmingham   (United States)

^b and Clinical Center   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

amphotericin B; antifungal prophylaxis; fluconazole; heart transplant; itraconazole; kidney transplant; liver transplant; lung transplant; solid organ transplantation; voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZATHIOPRINE; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MYCOPHENOLIC ACID; NYSTATIN; PLACEBO; POSACONAZOLE; PYRROLE DERIVATIVE; TACROLIMUS; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ASPERGILLUS; BACTERIAL PERITONITIS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GRAFT RECIPIENT; HEART FAILURE; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INTESTINE TRANSPLANTATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG ASPERGILLOSIS; LUNG INSUFFICIENCY; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS INSUFFICIENCY; PANCREAS TRANSPLANTATION; REVIEW; SMALL INTESTINE DISEASE; TREATMENT DURATION;

ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; FUNGI; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MYCOSES; PANCREAS TRANSPLANTATION; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 79957592741     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.29     Document Type: Review

References (68)

1. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med. Mycol. 45, 305-320 (2007).
2. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect. Dis. Clin. North Am. 17, 113-134 (2003).
3. Paya CV. Fungal infections in solid-organ transplantation. Clin. Infect. Dis. 16, 677-688 (1993).
4. Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect. Dis. Clin. North Am. 9, 1045-1074 (1995).
5. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50, 1101-1111 (2010). The results of a multicenter consortium provide excellent surveillance data on the epidemiology of invasive fungal infections (IFIs) in the solid organ transplantation (SOT) population.
6. Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am. J. Transplant. 8, 426-431 (2008).
7. Imataki O, Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T. Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematologic malignancies. Support Care Cancer DOI: 10.1007/s00520-010-0998-3 (2010) (Epub ahead of print).
8. Kusne S, Torre-Cisneros J, Manez R et al. Factors associated with invasive lung aspergillosis and significance of positive cultures after liver transplantation. J. Infect. Dis. 166, 1379-1383 (1992).
9. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 78, 123-138 (1999).
10. Singh N, Avery RK, Munoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin. Infect. Dis. 36, 46-52 (2003).
11. Husain S, Tollemar J, Dominguez EA et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 75, 2023-2029 (2003).
12. Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 73, 63-67 (2002).
13. Collins LA, Samore MH, Roberts MS et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J. Infect. Dis. 170, 644-652 (1994).
14. Singh N, Avery RK, Munoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin. Infect. Dis. 36, 46-52 (2003).
15. Patel R, Portela D, Badley A et al. Risk factors of invasive Candida and non- Candida fungal infections after liver transplantation. Transplantation 62, 926-934 (1996).
16. Wade JJ, Rolando N, Hayllar K, Philpott- Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 21, 1328-1336 (1995).
17. Karchmer AW, Samore MH, Hadley S, Collins LA, Jenkins L, Lewis WD. Fungal infections complicating orthotopic liver transplantation. Trans. Am. Clin. Climatol. Assoc. 106, 38-48 (1995).
18. Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect. Transplant. 14, 375-382 (1995).
19. Tollemar J, Höckerstedt K, Ericzon BG, Jalanko H, Ringdén O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 59, 45-50 (1995).
20. Lorf T, Braun F, Rüchel R, Müller A, Sattler B, Ringe B. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation. Mycoses 42, 47-53 (1999).
21. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 131, 729-737 (1999).
22. Lumbreras C, Cuervas-Mons V, Jara P et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J. Infect. Dis. 174, 583-588 (1996).
23. Biancofiore G, Bindi ML, Baldassarri R et al. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transpl. Int. 15, 341-347 (2002).
24. Sharpe MD, Ghent C, Grant D, Horbay GL, McDougal J, Colby WD. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 76, 977-983 (2003).
25. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 74, 688-695 (2002).
26. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 71, 910-913 (2001).
27. Pappas PG, Andes D, Schuster M et al. Invasive fungal infections in low-risk liver transplant recipients: a multicenter prospective observational study. Am. J. Transplant. 6, 386-391 (2006).
28. Hadley S, Huckabee C, Pappas PG et al. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl. Infect. Dis. 11, 40-48 (2009).
29. Castroagudin JF, Ponton C, Bustamante M et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Tranplant. Proc. 37, 3965-3967 (2005).
30. Playford EG, Webster AC, Sorrell TC, Craig JC. Systematic review and metaanalysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis. 25, 549-561 (2006). This outstanding review synthesizes the prospective data on antifungal prophylaxis in liver transplant recipients.
31. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl. 12, 850-858 (2006). This excellent paper also assimilates multiple prospective trials on antifungal prophylaxis in liver transplant recipients into one review.
32. Fortún J, Martín-Dávila P, Montejo M et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 87, 424-435 (2009). This is the only published data on the use of an echinocandin antifungal agent for prophylaxis in liver transplant recipients.
33. Kubak BM. Fungal infection in lung transplantation. Transpl. Infect. Dis. 4, 24-31 (2002).
34. Baddley JB, Andes DR, Marr KA et al. Factors associated with mortality in transplant patients with invasive Aspergillosis. Clin. Infect. Dis. 50, 1559-1567 (2010).
35. Minari A, Husni R, Avery RK et al. The incidence of invasive Aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl. Infect. Dis. 4, 195-200 (2002). One of the first to demonstrate the importance of universal prophylaxis among lung transplant recipients.
36. Sole A, Morant P, Salavert M et al. Aspergillus fumigatus in lung transplant recipients: risk factors and outcome. Clin. Microbiol. Infect. 11, 359-365 (2005).
37. Valentine VG, Gupta MR, Walker JE et al. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J. Heart Lung Transplant. 28, 163-169 (2009).
38. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and immunosuppressants. Pharmacotherapy 26, 1730-1744 (2006).
39. Westney GE, Kesten S, Hoyos A et al. Aspergillus infection in single and double lung transplant recipients. Transplantation 61, 915-919 (1996).
40. Husni RN, Gordon SM, Longworth DL et al. Cytomegalovirus infection is a risk factor for invasive Aspergillosis in lung transplant recipients. Clin. Infect. Dis. 26, 753-755 (1998).
41. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med. Mycol. 45, 305-320 (2007).
42. Singh N, Husain S. Invasive aspergillosis in solid organ transplant recipients. Am. J. Transplant. 9, S180-S191 (2009).
43. Dummer JS, Lazariashvilli N, Barnes J et al. A survey of anti-fungal management in lung transplantation. J. Heart Lung Transplant. 23, 1376-1381 (2003).
44. Husain S, Zaldonis D, Kusne S et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl. Infect. Dis. 8, 213-218 (2006).
45. Borro JM, Sole A, de la Torre M et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant. Proc. 40, 3090-3093 (2008).
46. Husain S, Paterson DL, Studer S et al. Voriconazole prophylaxis in lung transplant recipients. Am. J. Transplant. 6, 3008-3016 (2006).
47. Erjavec Z, Woolthuis GM, de Vries- Hospers HG et al. Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary Aspergillosis in haematological patients. Eur. J. Clin. Microbiol. Infect. Dis. 16, 364-368 (1997).
48. Monforte V, Roman A, Gavalda J et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: a study of risk factors. J. Heart Lung Transplant. 20, 1274-1281 (2001).
49. Drew RH, Ashley EA, Benjamin DK et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung transplant recipients. Transplantation 77, 232-237 (2004).
50. Reichenspurner H, Gamberg P, Nitschke M et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant. Proc. 29, 627-628 (1997).
51. Muñoz P, Rodríguez C, Bouza E et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am. J. Transplant. 4, 636-643 (2004). This study provides the best data on antifungal prophylaxis in heart transplant recipients.
52. Albano L, Bretagne S, Mamzer-Bruneel MF. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin. Infect. Dis. 48, 194-202 (2009).
53. Panackal AA, Dahlman A, Keil KT et al. Outbreak of invasive aspergillosis among renal transplant recipients. Transplantation 75, 1050-1053 (2003).
54. Benedetti E, Gruessner AC, Troppmann C et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J. Am. Coll. Surg. 183, 307-316 (1996).
55. Humar A, Kandaswamy R, Granger D, Gruessner RW, Gruessner AC, Sutherland DE. Decreased surgical risks of pancreas transplantation in the modern era. Ann. Surg. 231, 269-275 (2000).
56. Guaraldi G, Cocchi S, Codeluppi M. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients. Transplantation 80, 1742-1748 (2005).
57. Akamatsu N, Sugawara Y, Kaneko J et al. Preemptive treatment of fungal infection based on plasma (1→3) β-D-glucan levels after liver transplantation. Infection 35, 346-351 (2007).
58. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin. Microbiol. Infect. 15, 93-97 (2009).
59. Singh N. Antifungal prophylaxis in solid organ transplant recipients: considerations for clinical trial design. Clin. Infect. Dis. 39, S200-S206 (2004).
60. Vehreschild JJ, Rüping MJ, Wisplinghoff H et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J. Antimicrob. Chemother. 65, 1466-1471 (2010).
61. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356, 335-347 (2007).
62. Sánchez-Ortega I, Patiño B, Arnan M et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant. DOI: 10.1038/bmt.2010.185 (2010) (Epub ahead of print).
63. Alexander BD, Perfect JR, Daly JS et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 86, 791-796 (2008).
64. Scientific Registry of Transplant Recipients www.ustransplant.org
65. Liver Transplant European Study Into the Prevention of Fungal Infection (TENPIN) http://clinicaltrials.gov/ct2/show/NCT01058174
66. Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients http://clinicaltrials.gov/ct2/show/NCT00841971
67. Voriconazole as Prophylaxis for Liver Transplant Recipients http://clinicaltrials.gov/ct2/show/NCT00177788
68. Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation http://clinicaltrials.gov/ct2/show/ NCT00986713